A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Summary

The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.

Timeline

Start

2024-04-04

Primary completion

2026-10-23

Completion

2028-02-28

Publications

• Skoulidis F, Borghaei H, Garon EB, Leal TA, Kaufman J, Liu SV, Nadler E, Patel SP, Peters S, Ricciuti B, Gautam A, Emeribe U, Luciani-Silverman L, Heymach JV. Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study. Ther Adv Med Oncol. 2025 Nov 6;17:17588359251386611. doi: 10.1177/17588359251386611. eCollection 2025.

Drugs

Indications